Primary Chondrosarcomas of the Skull Base: A Systematic Review

Introduction: Primary skull base chondrosarcomas (SBCs) are rare intracranial neoplasms that can show invasive growth patterns. Surgical resection is the current standard but poses several risks. Photon and proton-based radiotherapy represent additional feasible treatments.

Objective: To systematically review clinical characteristics and management strategies of patients with primary SBCs.

Methods: We searched PubMed, EMBASE, Scopus, Web-of-Science, and Cochrane upon the PRISMA statement. Studies reporting clinical outcomes data of patients with primary SBCs were included. Clinical characteristics, management strategies, and treatment outcomes were analyzed.

Results: We included 32 studies comprising 1,288 patients. Median age at diagnosis was 42.5 years (range, 18–85). Tumors mostly infiltrated the middle fossa (72.1%), involving the petrous bone (36.9%), the clivus (22%), and the petroclival synchondrosis (20.7%). Less frequently, SBCs infiltrated the anterior fossa (12.8%), involving the supra/parasellar region (7.1%) and/or the orbit (2.1%), and the posterior fossa, extending to the jugular foramen (3%) and/or the foramen magnum (1.3%). Tumors invaded the cavernous sinus in 41.6% patients and caused extra-axial compression of the brainstem and the optic apparatus in 50.7% and 39.6% cases. Median duration of symptoms was 16 months (range, 0.1–312), with diplopia (28.3%) and headache (22.1%) being the most common. Cranial neuropathies were reported in 791 patients (61.4%). The fifth (19.7%) and the sixth (30.8%) cranial nerves were most commonly involved, and 161 patients (20.3%) had multiple neuropathies. 29 patients (3.7%) presented with hypopituitarism. Median tumor volume was 24.3 cm³ (range, 1.6–88.4). At histopathology, conventional SBCs were the most common (86.6%), followed by myxoid (7.7%), mesenchymal (5.7%), and undifferentiated (0.4%) tumors. Surgical resection (93.2%) was preferred over biopsy (6.8%), with subtotal and gross-total resection obtained in 46.6% and 36.7% patients, respectively. The most frequent open surgical approaches were the frontotemporal orbitozygomatic (18.3%) and the pterional (12.4%) approaches. A total of 92 patients (7.7%) underwent endoscopic resection through an endonasal route, and 17 patients (1.4%) received combined endoscopic plus open surgical resection. Postoperative cerebrospinal fluid leaks occurred in 35 patients (2.7%). Transient post-surgical complications were described in 85 patients (7.1%), mostly new cranial neuropathies (64.7%) and meningitis (18.8%), while persistent complications were reported in 59 patients (4.9%), mostly new cranial neuropathies (62.7%) and intracerebral hemorrhages (13.6%). A total of 1014 patients (78.7%) received radiotherapy: photon-based in 417 (41.1%), proton-based in 654 (64.5%), and carbon-based in 133 (13.1%). 261 patients (25.7%) experienced post-radiotherapy complications, with hypopituitarism (48.3%), hearing loss (22.2%), and radionecrosis (11.5%) being the most common. At posttreatment follow-up, symptomatic improvement was described in 46.7% patients, and most radiotherapy-treated lesions showed radiological stable volumes (58.3%) or tumor shrinkage (27.1%). Median follow-up was 67 months (range, 0.1–376). SBCs recurrences were reported in 210 cases (16.3%), with 5-year and 10-year local control rates of 84.3% and 67.4%, respectively. Most patients were alive at last follow-up (88.8%), with 5-year and 10-year overall survival rates of 94% and 84%, respectively.

Conclusion: Primary SBCs can severely impair clinical status and quality-of-life. Both surgical resection and radiotherapy are effective treatments, with low rates of complications and favorable rates of local tumor control.

 

MissingLinkText

Die Autoren geben an, dass kein Interessenkonflikt besteht.

Publikationsverlauf

Artikel online veröffentlicht:
15. Februar 2022